Boston Scientific Corporation (NYSE: BSX) Stock Competitors & Peer Comparison
See BSX's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BSX and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BSX | $42.75 | -4.23% | 62B | 13.79 | $3.10 | N/A |
| ABT | $109.93 | -3.23% | 190.3B | 21.10 | $5.21 | +2.28% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $101.80 | -2.90% | 130.2B | 18.41 | $5.53 | +2.81% |
| SYK | $325.87 | -2.75% | 124.1B | 24.34 | $13.39 | +1.09% |
| EW | $102.14 | +1.31% | 58.9B | 37.82 | $2.70 | N/A |
| GEHC | $82.38 | -1.64% | 37.2B | 16.81 | $4.90 | +0.18% |
| PHG | $30.35 | -0.52% | 29.7B | 17.34 | $1.75 | +3.27% |
| DXCM | $79.41 | -5.98% | 29.6B | 31.14 | $2.55 | N/A |
| ZBH | $105.59 | -1.18% | 20.1B | 12.45 | $8.48 | +0.91% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
BSX vs ABT Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, ABT has a market cap of 190.3B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while ABT trades at $109.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas ABT's P/E ratio is 21.10. In terms of profitability, BSX's ROE is +0.14%, compared to ABT's ROE of +0.09%. Regarding short-term risk, BSX is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for BSX.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
BSX vs BSX-PA Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BSX's ROE is +0.14%, compared to BSX-PA's ROE of +0.14%. Regarding short-term risk, BSX is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for BSX.Check BSX-PA's competition here
Medtronic Plc (NYSE: MDT)
BSX vs MDT Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, MDT has a market cap of 130.2B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while MDT trades at $101.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas MDT's P/E ratio is 18.41. In terms of profitability, BSX's ROE is +0.14%, compared to MDT's ROE of +0.11%. Regarding short-term risk, BSX is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for BSX.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
BSX vs SYK Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, SYK has a market cap of 124.1B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while SYK trades at $325.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas SYK's P/E ratio is 24.34. In terms of profitability, BSX's ROE is +0.14%, compared to SYK's ROE of +0.16%. Regarding short-term risk, BSX is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for BSX.Check SYK's competition here
Edwards Lifesciences Corporation (NYSE: EW)
BSX vs EW Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, EW has a market cap of 58.9B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while EW trades at $102.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas EW's P/E ratio is 37.82. In terms of profitability, BSX's ROE is +0.14%, compared to EW's ROE of +0.10%. Regarding short-term risk, BSX is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for BSX.Check EW's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
BSX vs GEHC Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, GEHC has a market cap of 37.2B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while GEHC trades at $82.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas GEHC's P/E ratio is 16.81. In terms of profitability, BSX's ROE is +0.14%, compared to GEHC's ROE of +0.16%. Regarding short-term risk, BSX is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for BSX.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
BSX vs PHG Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, PHG has a market cap of 29.7B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while PHG trades at $30.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas PHG's P/E ratio is 17.34. In terms of profitability, BSX's ROE is +0.14%, compared to PHG's ROE of +0.08%. Regarding short-term risk, BSX is less volatile compared to PHG. This indicates lower risk in terms of short-term price fluctuations for BSX.Check PHG's competition here
DexCom, Inc. (NASDAQ: DXCM)
BSX vs DXCM Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, DXCM has a market cap of 29.6B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while DXCM trades at $79.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas DXCM's P/E ratio is 31.14. In terms of profitability, BSX's ROE is +0.14%, compared to DXCM's ROE of +0.37%. Regarding short-term risk, BSX is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for BSX.Check DXCM's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
BSX vs ZBH Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, ZBH has a market cap of 20.1B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while ZBH trades at $105.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas ZBH's P/E ratio is 12.45. In terms of profitability, BSX's ROE is +0.14%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, BSX is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for BSX.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
BSX vs ABMD Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BSX's ROE is +0.14%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BSX is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for BSX.Check ABMD's competition here
Glaukos Corporation (NYSE: GKOS)
BSX vs GKOS Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, GKOS has a market cap of 13.3B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while GKOS trades at $224.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas GKOS's P/E ratio is -260.83. In terms of profitability, BSX's ROE is +0.14%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, BSX is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for BSX.Check GKOS's competition here
Smith & Nephew plc (NYSE: SNN)
BSX vs SNN Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, SNN has a market cap of 13.1B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while SNN trades at $31.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas SNN's P/E ratio is 21.03. In terms of profitability, BSX's ROE is +0.14%, compared to SNN's ROE of +0.12%. Regarding short-term risk, BSX is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for BSX.Check SNN's competition here
Penumbra, Inc. (NYSE: PEN)
BSX vs PEN Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while PEN trades at $319.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas PEN's P/E ratio is 83.37. In terms of profitability, BSX's ROE is +0.14%, compared to PEN's ROE of +0.10%. Regarding short-term risk, BSX is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for BSX.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
BSX vs SWAV Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BSX's ROE is +0.14%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, BSX is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for BSX.Check SWAV's competition here
Align Technology, Inc. (NASDAQ: ALGN)
BSX vs ALGN Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, ALGN has a market cap of 11.8B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while ALGN trades at $166.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas ALGN's P/E ratio is 15.14. In terms of profitability, BSX's ROE is +0.14%, compared to ALGN's ROE of +0.12%. Regarding short-term risk, BSX is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for BSX.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
BSX vs BIO Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while BIO trades at $381.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas BIO's P/E ratio is 41.12. In terms of profitability, BSX's ROE is +0.14%, compared to BIO's ROE of +0.14%. Regarding short-term risk, BSX is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for BSX.Check BIO's competition here
Insulet Corp. (NASDAQ: PODD)
BSX vs PODD Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, PODD has a market cap of 10.2B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while PODD trades at $146.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas PODD's P/E ratio is 24.96. In terms of profitability, BSX's ROE is +0.14%, compared to PODD's ROE of +0.29%. Regarding short-term risk, BSX is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for BSX.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
BSX vs BIO-B Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, BIO-B has a market cap of 9.9B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while BIO-B trades at $374.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas BIO-B's P/E ratio is -65.97. In terms of profitability, BSX's ROE is +0.14%, compared to BIO-B's ROE of +0.14%. Regarding short-term risk, BSX is less volatile compared to BIO-B. This indicates lower risk in terms of short-term price fluctuations for BSX.Check BIO-B's competition here
Globus Medical, Inc. (NYSE: GMED)
BSX vs GMED Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, GMED has a market cap of 9.5B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while GMED trades at $71.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas GMED's P/E ratio is 16.00. In terms of profitability, BSX's ROE is +0.14%, compared to GMED's ROE of +0.12%. Regarding short-term risk, BSX is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for BSX.Check GMED's competition here
Masimo Corporation (NASDAQ: MASI)
BSX vs MASI Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas MASI's P/E ratio is 44.43. In terms of profitability, BSX's ROE is +0.14%, compared to MASI's ROE of +0.09%. Regarding short-term risk, BSX is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for BSX.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
BSX vs BRKR Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, BRKR has a market cap of 9.3B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while BRKR trades at $61.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas BRKR's P/E ratio is 30.81. In terms of profitability, BSX's ROE is +0.14%, compared to BRKR's ROE of -0.05%. Regarding short-term risk, BSX is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for BSX.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
BSX vs BRKRP Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, BRKRP has a market cap of 9.3B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while BRKRP trades at $446.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas BRKRP's P/E ratio is 244.34. In terms of profitability, BSX's ROE is +0.14%, compared to BRKRP's ROE of -0.05%. Regarding short-term risk, BSX is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for BSX.Check BRKRP's competition here
Haemonetics Corporation (NYSE: HAE)
BSX vs HAE Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, HAE has a market cap of 5.5B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while HAE trades at $119.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas HAE's P/E ratio is 23.93. In terms of profitability, BSX's ROE is +0.14%, compared to HAE's ROE of +0.12%. Regarding short-term risk, BSX is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for BSX.Check HAE's competition here
LivaNova PLC (NASDAQ: LIVN)
BSX vs LIVN Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, LIVN has a market cap of 4.9B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while LIVN trades at $89.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas LIVN's P/E ratio is 21.37. In terms of profitability, BSX's ROE is +0.14%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, BSX is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for BSX.Check LIVN's competition here
Inari Medical, Inc. (NASDAQ: NARI)
BSX vs NARI Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas NARI's P/E ratio is -59.24. In terms of profitability, BSX's ROE is +0.14%, compared to NARI's ROE of -0.00%. Regarding short-term risk, BSX is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for BSX.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
BSX vs ITGR Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while ITGR trades at $126.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas ITGR's P/E ratio is 19.94. In terms of profitability, BSX's ROE is +0.14%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, BSX is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for BSX.Check ITGR's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
BSX vs TMDX Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while TMDX trades at $88.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas TMDX's P/E ratio is 44.77. In terms of profitability, BSX's ROE is +0.14%, compared to TMDX's ROE of +0.28%. Regarding short-term risk, BSX is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for BSX.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
BSX vs AXGN Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, AXGN has a market cap of 3B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while AXGN trades at $50.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas AXGN's P/E ratio is 131.53. In terms of profitability, BSX's ROE is +0.14%, compared to AXGN's ROE of -0.11%. Regarding short-term risk, BSX is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for BSX.Check AXGN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
BSX vs IRTC Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, IRTC has a market cap of 3B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while IRTC trades at $90.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas IRTC's P/E ratio is -209.53. In terms of profitability, BSX's ROE is +0.14%, compared to IRTC's ROE of -0.23%. Regarding short-term risk, BSX is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for BSX.Check IRTC's competition here
Neogen Corporation (NASDAQ: NEOG)
BSX vs NEOG Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while NEOG trades at $11.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas NEOG's P/E ratio is 42.00. In terms of profitability, BSX's ROE is +0.14%, compared to NEOG's ROE of -0.03%. Regarding short-term risk, BSX is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for BSX.Check NEOG's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
BSX vs UFPT Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while UFPT trades at $303.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas UFPT's P/E ratio is 30.94. In terms of profitability, BSX's ROE is +0.14%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, BSX is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for BSX.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
BSX vs NUVA Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BSX's ROE is +0.14%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BSX is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for BSX.Check NUVA's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
BSX vs ESTA Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, ESTA has a market cap of 2B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while ESTA trades at $67.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas ESTA's P/E ratio is -53.24. In terms of profitability, BSX's ROE is +0.14%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, BSX is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for BSX.Check ESTA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
BSX vs INSP Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, INSP has a market cap of 1.9B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while INSP trades at $63.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas INSP's P/E ratio is 28.18. In terms of profitability, BSX's ROE is +0.14%, compared to INSP's ROE of +0.12%. Regarding short-term risk, BSX is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for BSX.Check INSP's competition here
Butterfly Network, Inc. (NYSE: BFLY)
BSX vs BFLY Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, BFLY has a market cap of 1.7B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while BFLY trades at $6.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas BFLY's P/E ratio is -26.52. In terms of profitability, BSX's ROE is +0.14%, compared to BFLY's ROE of -0.28%. Regarding short-term risk, BSX is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for BSX.Check BFLY's competition here
Enovis Corporation (NYSE: ENOV)
BSX vs ENOV Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, ENOV has a market cap of 1.6B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while ENOV trades at $27.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas ENOV's P/E ratio is 7.77. In terms of profitability, BSX's ROE is +0.14%, compared to ENOV's ROE of -0.36%. Regarding short-term risk, BSX is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for BSX.Check ENOV's competition here
Novocure Ltd (NASDAQ: NVCR)
BSX vs NVCR Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, NVCR has a market cap of 1.6B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while NVCR trades at $13.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas NVCR's P/E ratio is -12.52. In terms of profitability, BSX's ROE is +0.14%, compared to NVCR's ROE of -0.36%. Regarding short-term risk, BSX is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for BSX.Check NVCR's competition here
CONMED Corporation (NYSE: CNMD)
BSX vs CNMD Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while CNMD trades at $51.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas CNMD's P/E ratio is 11.32. In terms of profitability, BSX's ROE is +0.14%, compared to CNMD's ROE of +0.07%. Regarding short-term risk, BSX is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for BSX.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
BSX vs HSKA Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BSX's ROE is +0.14%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BSX is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for BSX.Check HSKA's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
BSX vs LMRI Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, LMRI has a market cap of 1.3B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while LMRI trades at $13.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas LMRI's P/E ratio is -26.07. In terms of profitability, BSX's ROE is +0.14%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, BSX is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for BSX.Check LMRI's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
BSX vs TNDM Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while TNDM trades at $16.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas TNDM's P/E ratio is -18.18. In terms of profitability, BSX's ROE is +0.14%, compared to TNDM's ROE of -0.36%. Regarding short-term risk, BSX is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for BSX.Check TNDM's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
BSX vs PRCT Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while PRCT trades at $20.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas PRCT's P/E ratio is -10.62. In terms of profitability, BSX's ROE is +0.14%, compared to PRCT's ROE of -0.33%. Regarding short-term risk, BSX is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for BSX.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
BSX vs AVNS Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas AVNS's P/E ratio is 27.77. In terms of profitability, BSX's ROE is +0.14%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, BSX is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for BSX.Check AVNS's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
BSX vs ATEC Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while ATEC trades at $7.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas ATEC's P/E ratio is -13.21. In terms of profitability, BSX's ROE is +0.14%, compared to ATEC's ROE of -5.47%. Regarding short-term risk, BSX is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for BSX.Check ATEC's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
BSX vs SILK Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas SILK's P/E ratio is -18.96. In terms of profitability, BSX's ROE is +0.14%, compared to SILK's ROE of -0.35%. Regarding short-term risk, BSX is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for BSX.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
BSX vs FNA Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas FNA's P/E ratio is -19.83. In terms of profitability, BSX's ROE is +0.14%, compared to FNA's ROE of -0.35%. Regarding short-term risk, BSX is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for BSX.Check FNA's competition here
IRadimed Corporation (NASDAQ: IRMD)
BSX vs IRMD Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while IRMD trades at $86.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas IRMD's P/E ratio is 43.16. In terms of profitability, BSX's ROE is +0.14%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, BSX is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for BSX.Check IRMD's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
BSX vs SIBN Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, SIBN has a market cap of 1.1B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while SIBN trades at $24.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas SIBN's P/E ratio is -71.29. In terms of profitability, BSX's ROE is +0.14%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, BSX is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for BSX.Check SIBN's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
BSX vs IART Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, IART has a market cap of 1B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while IART trades at $13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas IART's P/E ratio is 5.69. In terms of profitability, BSX's ROE is +0.14%, compared to IART's ROE of +0.01%. Regarding short-term risk, BSX is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for BSX.Check IART's competition here
CeriBell, Inc. (NASDAQ: CBLL)
BSX vs CBLL Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, CBLL has a market cap of 1B. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while CBLL trades at $26.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas CBLL's P/E ratio is -15.12. In terms of profitability, BSX's ROE is +0.14%, compared to CBLL's ROE of -0.55%. Regarding short-term risk, BSX is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for BSX.Check CBLL's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
BSX vs AHCO Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, AHCO has a market cap of 998.7M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while AHCO trades at $7.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas AHCO's P/E ratio is 14.95. In terms of profitability, BSX's ROE is +0.14%, compared to AHCO's ROE of -0.29%. Regarding short-term risk, BSX is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for BSX.Check AHCO's competition here
Artivion, Inc. (NYSE: AORT)
BSX vs AORT Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, AORT has a market cap of 985.1M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while AORT trades at $20.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas AORT's P/E ratio is 33.67. In terms of profitability, BSX's ROE is +0.14%, compared to AORT's ROE of -0.04%. Regarding short-term risk, BSX is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for BSX.Check AORT's competition here
Picard Medical, Inc. (AMEX: PMI)
BSX vs PMI Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, PMI has a market cap of 877.7M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while PMI trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas PMI's P/E ratio is -7.12. In terms of profitability, BSX's ROE is +0.14%, compared to PMI's ROE of -9.31%. Regarding short-term risk, BSX is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for BSX.Check PMI's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
BSX vs CSII Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas CSII's P/E ratio is -20.83. In terms of profitability, BSX's ROE is +0.14%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BSX is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for BSX.Check CSII's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
BSX vs KIDS Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, KIDS has a market cap of 829.5M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while KIDS trades at $31.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas KIDS's P/E ratio is -23.71. In terms of profitability, BSX's ROE is +0.14%, compared to KIDS's ROE of -0.10%. Regarding short-term risk, BSX is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for BSX.Check KIDS's competition here
Varex Imaging Corporation (NASDAQ: VREX)
BSX vs VREX Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, VREX has a market cap of 783.4M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while VREX trades at $18.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas VREX's P/E ratio is 19.42. In terms of profitability, BSX's ROE is +0.14%, compared to VREX's ROE of +0.05%. Regarding short-term risk, BSX is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for BSX.Check VREX's competition here
InMode Ltd. (NASDAQ: INMD)
BSX vs INMD Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, INMD has a market cap of 767.6M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while INMD trades at $13.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas INMD's P/E ratio is 9.26. In terms of profitability, BSX's ROE is +0.14%, compared to INMD's ROE of +0.12%. Regarding short-term risk, BSX is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for BSX.Check INMD's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
BSX vs CTKB Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, CTKB has a market cap of 760.4M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while CTKB trades at $5.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas CTKB's P/E ratio is -30.99. In terms of profitability, BSX's ROE is +0.14%, compared to CTKB's ROE of -0.25%. Regarding short-term risk, BSX is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for BSX.Check CTKB's competition here
Bioventus Inc. (NASDAQ: BVS)
BSX vs BVS Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, BVS has a market cap of 725.1M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while BVS trades at $10.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas BVS's P/E ratio is 13.93. In terms of profitability, BSX's ROE is +0.14%, compared to BVS's ROE of +0.27%. Regarding short-term risk, BSX is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for BSX.Check BVS's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
BSX vs BBNX Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, BBNX has a market cap of 706.8M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while BBNX trades at $15.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas BBNX's P/E ratio is -8.54. In terms of profitability, BSX's ROE is +0.14%, compared to BBNX's ROE of -0.27%. Regarding short-term risk, BSX is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for BSX.Check BBNX's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
BSX vs PACB Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, PACB has a market cap of 700.9M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while PACB trades at $2.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas PACB's P/E ratio is -5.50. In terms of profitability, BSX's ROE is +0.14%, compared to PACB's ROE of +6.04%. Regarding short-term risk, BSX is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for BSX.Check PACB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
BSX vs SRDX Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas SRDX's P/E ratio is -34.66. In terms of profitability, BSX's ROE is +0.14%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, BSX is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for BSX.Check SRDX's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
BSX vs TCMD Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, TCMD has a market cap of 583.1M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while TCMD trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas TCMD's P/E ratio is 24.10. In terms of profitability, BSX's ROE is +0.14%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, BSX is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for BSX.Check TCMD's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
BSX vs APEN Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas APEN's P/E ratio is -9.43. In terms of profitability, BSX's ROE is +0.14%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BSX is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for BSX.Check APEN's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
BSX vs SGHT Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, SGHT has a market cap of 556.4M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while SGHT trades at $10.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas SGHT's P/E ratio is -18.04. In terms of profitability, BSX's ROE is +0.14%, compared to SGHT's ROE of -0.52%. Regarding short-term risk, BSX is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for BSX.Check SGHT's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
BSX vs AVR Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, AVR has a market cap of 554.1M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while AVR trades at $5.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas AVR's P/E ratio is -2.93. In terms of profitability, BSX's ROE is +0.14%, compared to AVR's ROE of -0.78%. Regarding short-term risk, BSX is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for BSX.Check AVR's competition here
ZimVie Inc. (NASDAQ: ZIMV)
BSX vs ZIMV Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, BSX's ROE is +0.14%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, BSX is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for BSX.Check ZIMV's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
BSX vs DCTH Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, DCTH has a market cap of 518.4M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while DCTH trades at $14.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas DCTH's P/E ratio is 1494.00. In terms of profitability, BSX's ROE is +0.14%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, BSX is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for BSX.Check DCTH's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
BSX vs SENS Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, SENS has a market cap of 453.7M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while SENS trades at $8.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas SENS's P/E ratio is -3.85. In terms of profitability, BSX's ROE is +0.14%, compared to SENS's ROE of -1.66%. Regarding short-term risk, BSX is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for BSX.Check SENS's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
BSX vs SSII Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, SSII has a market cap of 430M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while SSII trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas SSII's P/E ratio is -35.75. In terms of profitability, BSX's ROE is +0.14%, compared to SSII's ROE of -0.27%. Regarding short-term risk, BSX is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for BSX.Check SSII's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
BSX vs NPCE Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, NPCE has a market cap of 428.4M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while NPCE trades at $12.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas NPCE's P/E ratio is -21.89. In terms of profitability, BSX's ROE is +0.14%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, BSX is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for BSX.Check NPCE's competition here
Avita Medical Inc. (NASDAQ: RCEL)
BSX vs RCEL Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, RCEL has a market cap of 412.4M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while RCEL trades at $16.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas RCEL's P/E ratio is -11.53. In terms of profitability, BSX's ROE is +0.14%, compared to RCEL's ROE of +1.46%. Regarding short-term risk, BSX is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for BSX.Check RCEL's competition here
Cerus Corporation (NASDAQ: CERS)
BSX vs CERS Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, CERS has a market cap of 406.9M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while CERS trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas CERS's P/E ratio is -66.94. In terms of profitability, BSX's ROE is +0.14%, compared to CERS's ROE of -0.11%. Regarding short-term risk, BSX is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for BSX.Check CERS's competition here
CapsoVision, Inc. (NASDAQ: CV)
BSX vs CV Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, CV has a market cap of 336M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while CV trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas CV's P/E ratio is -10.02. In terms of profitability, BSX's ROE is +0.14%, compared to CV's ROE of -1.78%. Regarding short-term risk, BSX is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for BSX.Check CV's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
BSX vs OFIX Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, OFIX has a market cap of 317.9M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while OFIX trades at $7.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas OFIX's P/E ratio is -5.12. In terms of profitability, BSX's ROE is +0.14%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, BSX is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for BSX.Check OFIX's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
BSX vs SMLR Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas SMLR's P/E ratio is 3.92. In terms of profitability, BSX's ROE is +0.14%, compared to SMLR's ROE of +0.20%. Regarding short-term risk, BSX is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for BSX.Check SMLR's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
BSX vs CLPT Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, CLPT has a market cap of 275.5M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while CLPT trades at $8.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas CLPT's P/E ratio is -7.28. In terms of profitability, BSX's ROE is +0.14%, compared to CLPT's ROE of -1.70%. Regarding short-term risk, BSX is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for BSX.Check CLPT's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
BSX vs INFU Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, INFU has a market cap of 273.5M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while INFU trades at $13.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas INFU's P/E ratio is 33.49. In terms of profitability, BSX's ROE is +0.14%, compared to INFU's ROE of +0.16%. Regarding short-term risk, BSX is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for BSX.Check INFU's competition here
Profound Medical Corp. (NASDAQ: PROF)
BSX vs PROF Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, PROF has a market cap of 263.8M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while PROF trades at $7.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas PROF's P/E ratio is -7.37. In terms of profitability, BSX's ROE is +0.14%, compared to PROF's ROE of -0.28%. Regarding short-term risk, BSX is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for BSX.Check PROF's competition here
Quantum-Si incorporated (NASDAQ: QSI)
BSX vs QSI Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, QSI has a market cap of 263.6M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while QSI trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas QSI's P/E ratio is -2.88. In terms of profitability, BSX's ROE is +0.14%, compared to QSI's ROE of -0.45%. Regarding short-term risk, BSX is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for BSX.Check QSI's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
BSX vs TMCI Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, TMCI has a market cap of 262.7M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while TMCI trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas TMCI's P/E ratio is -4.30. In terms of profitability, BSX's ROE is +0.14%, compared to TMCI's ROE of -0.76%. Regarding short-term risk, BSX is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for BSX.Check TMCI's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
BSX vs MGRM Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas MGRM's P/E ratio is -12.00. In terms of profitability, BSX's ROE is +0.14%, compared to MGRM's ROE of -1.17%. Regarding short-term risk, BSX is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for BSX.Check MGRM's competition here
Nevro Corp. (NYSE: NVRO)
BSX vs NVRO Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BSX's ROE is +0.14%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BSX is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for BSX.Check NVRO's competition here
Electromed, Inc. (AMEX: ELMD)
BSX vs ELMD Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, ELMD has a market cap of 223.4M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while ELMD trades at $27.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas ELMD's P/E ratio is 20.58. In terms of profitability, BSX's ROE is +0.14%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, BSX is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for BSX.Check ELMD's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
BSX vs TLSI Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, TLSI has a market cap of 199.5M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while TLSI trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas TLSI's P/E ratio is -1.93. In terms of profitability, BSX's ROE is +0.14%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, BSX is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for BSX.Check TLSI's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
BSX vs BSGM Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas BSGM's P/E ratio is -5.81. In terms of profitability, BSX's ROE is +0.14%, compared to BSGM's ROE of +6.96%. Regarding short-term risk, BSX is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for BSX.Check BSGM's competition here
RxSight, Inc. (NASDAQ: RXST)
BSX vs RXST Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, RXST has a market cap of 188.6M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while RXST trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas RXST's P/E ratio is -4.01. In terms of profitability, BSX's ROE is +0.14%, compared to RXST's ROE of -0.20%. Regarding short-term risk, BSX is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for BSX.Check RXST's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
BSX vs MDGS Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas MDGS's P/E ratio is -0.27. In terms of profitability, BSX's ROE is +0.14%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, BSX is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for BSX.Check MDGS's competition here
Neuronetics, Inc. (NASDAQ: STIM)
BSX vs STIM Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, STIM has a market cap of 163.4M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while STIM trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas STIM's P/E ratio is -4.87. In terms of profitability, BSX's ROE is +0.14%, compared to STIM's ROE of -1.28%. Regarding short-term risk, BSX is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for BSX.Check STIM's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
BSX vs QIPT Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas QIPT's P/E ratio is -15.87. In terms of profitability, BSX's ROE is +0.14%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, BSX is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for BSX.Check QIPT's competition here
Inogen, Inc. (NASDAQ: INGN)
BSX vs INGN Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, INGN has a market cap of 160M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while INGN trades at $6.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas INGN's P/E ratio is -6.63. In terms of profitability, BSX's ROE is +0.14%, compared to INGN's ROE of -0.20%. Regarding short-term risk, BSX is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for BSX.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
BSX vs QTRX Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, QTRX has a market cap of 137.1M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while QTRX trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas QTRX's P/E ratio is -1.14. In terms of profitability, BSX's ROE is +0.14%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, BSX is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for BSX.Check QTRX's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
BSX vs FOCL Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, FOCL has a market cap of 125.9M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while FOCL trades at $3.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas FOCL's P/E ratio is -3.25. In terms of profitability, BSX's ROE is +0.14%, compared to FOCL's ROE of -2.41%. Regarding short-term risk, BSX is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for BSX.Check FOCL's competition here
Owlet, Inc. (NYSE: OWLT)
BSX vs OWLT Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, OWLT has a market cap of 121.6M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while OWLT trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas OWLT's P/E ratio is -29.71. In terms of profitability, BSX's ROE is +0.14%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, BSX is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for BSX.Check OWLT's competition here
Pulmonx Corporation (NASDAQ: LUNG)
BSX vs LUNG Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, LUNG has a market cap of 109.9M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while LUNG trades at $2.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas LUNG's P/E ratio is -2.53. In terms of profitability, BSX's ROE is +0.14%, compared to LUNG's ROE of -0.98%. Regarding short-term risk, BSX is less volatile compared to LUNG. This indicates lower risk in terms of short-term price fluctuations for BSX.Check LUNG's competition here
iCAD, Inc. (NASDAQ: ICAD)
BSX vs ICAD Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas ICAD's P/E ratio is -20.37. In terms of profitability, BSX's ROE is +0.14%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, BSX is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for BSX.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
BSX vs HJLI Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas HJLI's P/E ratio is N/A. In terms of profitability, BSX's ROE is +0.14%, compared to HJLI's ROE of -0.70%. Regarding short-term risk, BSX is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for BSX.Check HJLI's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
BSX vs CATX Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, CATX has a market cap of 95.9M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while CATX trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas CATX's P/E ratio is -0.63. In terms of profitability, BSX's ROE is +0.14%, compared to CATX's ROE of -0.42%. Regarding short-term risk, BSX is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for BSX.Check CATX's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
BSX vs ASXC Comparison November 2026
Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSX stands at 62B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, BSX is priced at $42.75 on the NYSE, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSX currently has a P/E ratio of 13.79, whereas ASXC's P/E ratio is -1.12. In terms of profitability, BSX's ROE is +0.14%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, BSX is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for BSX.Check ASXC's competition here